HYNRCS-Allo - Corestem

Drug Profile

HYNRCS-Allo - Corestem

Alternative Names: Allogeneic bone marrow-derived mesenchymal stem cells (ALS) - Corestem; HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CORESTEM
  • Developer CORESTEM; Hanyang University
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis

Most Recent Events

  • 01 Feb 2017 Hanyang University and Corestem initiate a phase I trial for Amyotrophic lateral sclerosis in South Korea (Intrathecal) (NCT03214146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top